Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia

Rheumatology (United Kingdom)

Volumn 53, Issue 12, 2014, Pages 2167-2174

  Fleischmann, Roy ^a   Kerr, Bradley ^b   Yeh, Li Tain ^b   Suster, Matt ^b   Shen, Zancong ^b   Polvent, Elizabeth ^b   Hingorani, Vijay ^b   Quart, Barry ^b   Manhard, Kimberly ^b   Miner, Jeffrey N ^b   Baumgartner, Scott ^b  

^a METROPLEX CLINICAL RESEARCH CENTER   (United States)

^b Ardea Biosciences Inc   (United States)

Author keywords

Drug drug interaction; Febuxostat; Gout; Lesinurad; Pharmacodynamic; Pharmacokinetic; Selective uric acid reabsorption inhibitor; Xanthine oxidase inhibitor

Indexed keywords

COLCHICINE; CREATINE KINASE; FEBUXOSTAT; LESINURAD; URATE; URIC ACID; ANTIGOUT AGENT; THIAZOLE DERIVATIVE; THIOGLYCOLIC ACID DERIVATIVE; TRIAZOLE DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION AT STEADY-STATE; CREATINE KINASE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GOUT; HUMAN; HYPERURICEMIA; IN VITRO STUDY; KIDNEY CLEARANCE; KIDNEY CONCENTRATING CAPACITY; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE DRUG DOSE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT; TREATMENT DURATION; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; MIDDLE AGED;

ADULT; AGED; COLCHICINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; THIAZOLES; THIOGLYCOLATES; TRIAZOLES; URIC ACID;

EID: 84902502296     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket487     Document Type: Article

References (35)

1. Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004;50:2400-14.
2. Gout: Novel biologics rev up a slow market. Burlington, MA: Decision Resources, 2010.
3. de Oliveira EP, Burini RC. High plasma uric acid concentration:causes and consequences. Diabetol Metab Syndr 2012;4:12.
4. Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
5. Zhang W, Doherty M, Pascual E et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11.
6. Kim SY, Guevara JP, Kim KM et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009;61:885-92.
7. Richette P, Bardin T. Gout. Lancet 2010;375:318-28.
8. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010;12:223.
9. Ruggiero C, Cherubini A, Ble A et al. Uric acid and inflammatory markers. Eur Heart J 2006;27:1174-81.
10. Jordan KM, Cameron JS, Snaith M et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007;46:1372-4.
11. Emmerson BT. The management of gout. N Engl J Med 1996;334:445-51.
12. Perez-Ruiz F, Liote F. Lowering serum uric acid levels:what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007;57:1324-8.
13. Edwards NL. Treatment-failure gout: a moving target. Arthritis Rheum 2008;58:2587-90.
14. Darmawan J, Rasker JJ, Nuralim H. The effect of control and self-medication of chronic gout in a developing country. Outcome after 10 years. J Rheumatol 2003;30:2437-43.
15. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-5.
16. Pandya BJ, Riedel AA, Swindle JP et al. Relationship between physician specialty and allopurinol prescribing patterns: a study of patients with gout in managed care settings. Curr Med Res Opin 2011;27:737-44.
17. Becker MA, Schumacher HR Jr, Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
18. Becker MA, Schumacher HR, Espinoza LR et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010;12:R63.
19. Uloric [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, 2013.
20. Perez-Ruiz F, Calabozo M, Pijoan JI et al. Effect of uratelowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60.
21. Burns CM, Wortmann RL. Gout therapeutics: new drugs for an old disease. Lancet 2011;377:165-77.
22. Yeh L, Shen Z, Kerr B. RDEA594: a potent URAT1 inhibitor without affecting other important renal transporters, OAT1 and OAT 3 [abstract]. Ann Rheum Dis 2009;68:320.
23. Stamp LK, Jordan S. The challenges of gout management in the elderly. Drugs Aging 2011;28:591-603.
24. Sarawate CA, Brewer KK, Yang W et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-34.
25. Jansen TL, Reinders MK, van Roon EN et al. Benzbromarone withdrawn from the European market:another case of "absence of evidence is evidence of absence"? Clin Exp Rheumatol 2004;22:651.
26. Pandya BJ, Riedel AA, Becker LK et al. Renal impairment and poor outcomes of allopurinol therapy in US gout patients [abstract]. Arthritis Rheum 2009;60:702.
27. Tan PK, Hyndman D, Liu S et al. Lesinurad (RDEA594), a novel investigational uricosuric agent for hyperuricemia and gout, blocks transport of uric acid induced by hydrochlorothiazide [abstract]. Ann Rheum Dis 2011;70:187.
28. Wallace SL, Robinson H, Masi AT et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
29. Asplin JR. Uric acid stones. Semin Nephrol 1996;16:412-24.
30. Hess B. Prophylaxis of uric acid and cystine stones. Urol Res 1990;18(Suppl 1):S41-4.
31. Mertz DP, Eichhorn R. Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol? Klin Wochenschr 1984;62:1170-2.
32. Muller FO, Schall R, Groenewoud G et al. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. Eur J Clin Pharmacol 1993;44:69-72.
33. Khosravan R, Grabowski BA, Wu JT et al. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet 2006;45:821-41.
34. Ly J, Gow P, Dalbeth N. Colchicine prescribing and safety monitoring in patients with gout. N Z Med J 2007;120:U2808.
35. Galtier F, Mura T, Raynaud de ME et al. Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers. Toxicol Appl Pharmacol 2012;263:281-6.